Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Activated: IND.223

The primary objective of this study is to assess the clinical benefit rate (CBR) of palbociclib in patients with metastatic, castration-resistant prostate cancer (mCRPC).

Secondary objectives include:
  1. To determine the effect of palbociclib on PSA decline and time to PSA progression;
  2. To determine objective response as determined by RECIST 1.1 criteria;
  3. To evaluate the safety and toxicity profile of palbociclib in mCRPC patients.
Participation in this study is currently limited to invited centres.

If you have questions please contact the study coordinator Kim MacDonnell 613-533-6430.